Vanda Pharmaceuticals | VNDA - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Acadia Pharmaceuticals USD 279.64M 36.37M 2026-06
Agios Pharmaceuticals USD 19.43M 1.34M 2026-03
Akebia Therapeutics USD 47.28M 1.7M 2025-12
Alnylam Pharmaceuticals USD 992.69M 167.68M 2026-06
Anika Therapeutics USD 19.18M 3.6M 2025-12
Arrowhead Research USD 75.25M 1.52M 2026-06
AstraZeneca USD 12.86B 251M 2026-06
Bristol-Myers Squibb USD 9.26B 1.19B 2026-06
Eli Lilly USD 16.22B 301.7M 2026-03
Enanta Pharmaceuticals -22.29M 23.75M 2024-12
Halozyme Therapeutics USD 297.47M 75.53M 2026-03
Heron Therapeutics USD 29.47M 3.17M 2025-12
Insmed USD 356.19M 99.73M 2026-06
J&J USD 18.55B 1.31B 2026-06
Lexicon Pharmaceuticals USD 5.29M 8.88M 2025-12
Ligand Pharmaceuticals USD 100.41M 51.96M 2026-06
Merck USD 12.09B 1.24B 2026-03
Minerva Neurosciences -4.27M 26.79M 2024-12
Moderna USD -566M 792M 2026-03
Novartis USD 10.07B 758M 2026-03
Pfizer USD -248M 11.29B 2026-06
PTC Therapeutics USD 232.94M 84.56M 2026-03
Puma Biotechnology USD 20.32M 24.85M 2024-09
Sangamo BioSciences -2.39M 1.09M 2024-06
Sanofi EUR 8.71B 602M 2026-06
Takeda JPY 813.22B 124.39B 2026-06
Teva Pharmaceutical Industries USD 2.15B 45M 2026-06
Ultragenyx Pharmaceutical USD 180M 74M 2026-06
Vanda Pharmaceuticals USD 50.6M 5.5M 2024-12
Veracyte USD 108.55M 7.39M 2026-06